Efficacy and safety of nivolumab plus apatinib in advanced liver carcinosarcoma: a case report
Lingdi Zhao1, Yonghao Yang1, Quanli Gao1
1Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou City, Henan Province, China.
Abstract:
Liver carcinosarcoma is a rare malignancy usually seen in adults, majority of whom have a history of chronic hepatitis. Radical resection in early stages leads to better prognosis; however, the treatment regimen for patients at advanced stage is usually based on previously published case reports. At present, there is no report on programmed death-1 blockade and liver carcinosarcoma. Here, we report the case of a patient with advanced liver carcinosarcoma treated with nivolumab plus apatinib, which resulted in partial remission. However, grade 3 elevation of aminotransferase occurred during treatment, suggesting that the combination therapy should be recommended only after risk assessment. Nonetheless, programmed death-1 blockade plus apatinib might be a promising therapeutic approach for patients with advanced liver carcinosarcoma.
More Related Videos
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
08:25Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
Published on: June 5, 2020
Related Concept Videos
Survey Safety
Self-Efficacy
Household Wiring And Electrical Safety
Data Reporting and Recording
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:
Extraction: Advanced Methods
